Recombinant adeno-associated viruses (rAAVs) are promising vectors for gene therapy since they efficiently and stably transduce a variety of tissues of immunocompetent animals. The major disadvantage of rAAVs is their limited capacity to package foreign DNA (р5 kb). Often, co-expression of two or more genes from a single viral vector is desirable to achieve maximal therapeutic efficacy or to track transduced cells in vivo by suitable reporter genes. The internal ribosome entry site (IRES) sequence of encephalomyocarditis virus has been widely used to construct bicistronic viral vectors. However, the IRES is rather long and IRES-mediated translation can be relatively inefficient when compared with capdependent translation. As an alternative to the IRES for in vivo gene expression, we studied the 16 amino-acid long 2A peptide of foot and mouth disease virus (FMDV). The 2A peptide mediates the primary cis-'cleavage' of the FMDV polyprotein in a cascade of processing events that ultimately
Introduction
Recombinant adeno-associated viruses (rAAVs) can infect both dividing and quiescent cells, are well tolerated and show low immunogenicity. [1] [2] [3] [4] [5] Numerous studies have demonstrated the ability of these vectors to mediate efficient and long-lasting gene expression in different tissues of immunocompetent animals. [6] [7] [8] [9] [10] [11] [12] [13] [14] Recently, progress has been made in identifying positions within the AAV capsid proteins that tolerate small insertions of targeting ligands without significantly affecting resultant viral titers. [15] [16] [17] Moreover, rAAV genomes can be packaged into capsids derived from other AAV serotypes, rendering them more efficient in infecting certain cell types. 18, 19 It is expected that these developments and ongoing efforts to obtain detailed structural information on the AAV capsid will expand the number of tissues and cells that can be targeted by AAV in the future. Unfortunately, rAAVs can only encapsidate transgene cassettes smaller than 5 kb in length. generate the mature FMDV proteins. We have generated several different rAAV genomes in which two coding regions are fused in-frame via the FMDV 2A sequence. We show that FMDV 2A efficiently mediates the generation of the expected cleavage products from the artificial fusion proteins in cells. Furthermore, we find that both EGFP and ␣-synuclein are expressed at substantially higher levels from 2A vectors than from the corresponding IRES-based vectors, while SOD-1 is expressed at comparable or slightly higher levels. Finally, we demonstrate for the first time, that the 2A sequence results in effective bicistronic gene expression in vivo after injection of 2A-dependent rAAVs into the rat substantia nigra. We conclude that 2A-containing rAAVs may represent an attractive alternative to IRESdependent vectors for ex vivo and in vivo gene expression and gene therapy. Gene Therapy (2001) 8, 864-873. adenovirus/AAV, 21 hybrid HSV/AAV, 22 and transcomplementing AAV 23 vectors have been generated as a potential solution to this problem. Nevertheless, the low insert capacity of rAAV remains a problem, in particular when two or more genes need to be expressed from a single rAAV.
The internal ribosome entry site (IRES) of encepahlomyocarditis virus (EMCV) has been widely used to link two genes transcribed from a single promoter within recombinant viral vectors. [24] [25] [26] However, the efficiency of IRES-dependent translation may vary in different cells and tissues [27] [28] [29] and IRES-dependent second gene expression can be significantly lower than cap-dependent first gene expression in bicistronic vectors. 30, 31 Furthermore, in consideration of the low insert capacity of rAAV vectors, an element promoting bicistronic expression but being shorter than the IRES may be preferred.
Picornavirus genomes contain a single open reading frame encoding a polyprotein of about 225 kDa. This polyprotein undergoes co-translational cleavages in cis to produce the primary cleavage products, and then is further processed to generate the mature viral proteins. 32 The first cleavage is mediated by the 2A sequence which cleaves at its own C-terminus (cardioviruses and aphthoviruses) or N-terminus (enteroviruses and rhinoviruses). The 2A region in foot and mouth disease virus (FMDV) spans only 16 amino acids. 33, 34 When engineered into heterologous fusion proteins, the FMDV 2A sequence has been shown to mediate cleavage both in vitro using eukaryotic translation systems, [33] [34] [35] as well as in plants 36, 37 and cultured mammalian cells. 38, 39 Recently, the FMDV 2A sequence has been incorporated into retroviral vectors, alone or combined with different IRES sequences to construct bicistronic, tricistronic and tetracistronic retroviral vectors. These vectors were shown to co-express resistance and reporter genes in producer lines and infected cultured fibroblasts. 40, 41 However, to date no results on the efficiency of 2A-mediated gene expression in animals and the potential of this system for in vivo gene therapy have been reported.
To further investigate the usefulness of the 2A sequence for the coordinate expression of two genes from a bicistronic viral (gene therapy) vector, we generated recombinant adeno-associated viral genomes encoding ␣-synuclein (syn) and EGFP or Cu/Zn superoxide dismutase (SOD-1) and EGFP linked via the FMDV 2A sequence. We assessed 2A-mediated cleavage by analyzing the various gene products by Western blot and confocal microscopy in transiently transfected cells. Moreover, we quantitatively compared 2A-and IRESmediated second gene expression for three different proteins. Finally, we generated rAAVs encoding syn-2A-EGFP and EGFP-2A-syn under the control of the neuronspecific human PDGF-␤ promoter, and compared them with a rAAV encoding ␣-synuclein and EGFP separated by the IRES element of EMCV with respect to their abilities to confer gene expression in rat substantia nigra neurons in vivo.
Results
Immunoblot analysis of FMDV 2A-mediated protein expression in transfected and rAAV-infected cells The CMV promoter-controlled plasmids encoding ␣-synuclein and EGFP or SOD1 and EGFP linked in-frame via the FMDV 2A protease sequence ( Figure 1a , b and d, e) were transiently transfected into 293T cells, and expression of EGFP and ␣-synuclein or SOD1 was assessed by Western blot analysis. As shown in Figure 2 , plasmid CMV-SOD1-2A-EGFP resulted in the generation of both expected cleavage products, SOD1-2A (Figure 2a . Since Pro-SOD1 (P-SOD1) co-migrates with endogenous SOD-1, we attribute the increased signal to the presence of Pro-SOD1 ( Figure 2a, lane 2) . In addition to the proteins generated by 2A-mediated cleavage, both plasmids also resulted in the synthesis of the full-length, unprocessed precursor proteins SOD1-2A-EGFP and EGFP-2A-SOD1 (Figure 2a,  b) . Based on the relative intensities of the immunoreactive bands on the Western blots, we estimated that about two-thirds of the precursor proteins were cleaved.
To demonstrate the utility of the FMDV 2A protease within the context of another fusion protein, we inserted the human ␣-synuclein coding sequence either upstream Gene Therapy
Figure 1 The vectors used in this study. (a) CMV-SOD1-2A-EGFP, (b) CMV-syn-2A-EGFP, (c) CMV-syn-2A*-EGFP (NPGP mutated to AAAA), (d) CMV-EGFP-2A-SOD1, (e) CMV-EGFP-2A-syn, (f) CMVsyn-IRES-EGFP, (g) CMV-EGFP-IRES-SOD1, (h) CMV-EGFP-IRESsyn, (i) PDGF-EGFP-2A-syn, (j) PDGF-syn-2A-EGFP, (k) PDGF-syn-IRES-EGFP.
or downstream of EGFP. The plasmids CMV-syn-2A-EGFP and CMV-EGFP-2A-syn resulted in the generation of both the unprocessed precursor proteins, as well as the expected cleavage products syn-2A (Figure 3a (Figure 3a, lanes 1 and 2) . In order to find out whether this protein was generated by cleavage of the 2A 'protease' at a second cryptic site within the N-terminal portion of EGFP, we mutated the NPGP motif of 2A to AAAA (four alanines) by PCR mutagenesis. The NPGP motif has previously been shown to be essential for 2A-mediated cleavage. 42 Mutation of NPGP to AAAA in plasmid CMV-syn-2A*-EGFP (Figure 1c ) completely prevented the generation of both syn-2A (Figure 3a , compare lanes 1 and 2) and Pro-EGFP (Figure 3b, compare lanes 1 and 2) . In contrast, the 35 kDa ␣-synuclein immunoreactive protein was unaffected by the mutagenesis of the conserved NPGP motif (compare lanes 1 and 2 in Figure 3a) , suggesting that this protein was not generated by 2A-mediated cleavage, and may be a degradation product of the unprocessed syn-2A-EGFP precursor (see also Discussion). Finally, to demonstrate processing of a 2A-containing fusion protein after rAAV infection, cells were transduced with a rAAV vector carrying the SOD1-2A-EGFP cassette, and 2A-dependent cleavage products were analyzed by Western 
synuclein (a) or a polyclonal antibody against EGFP (b). Cells were transfected with plasmid CMV-syn-2A-EGFP (lanes 1), CMV-syn-2A*-EGFP (NPGP mutated to AAAA; lanes 2), CMV-EGFP-2A-syn (lanes 3), positive control plasmid CMV-syn (lanes 5) or CMV-EGFP (lanes 6), or remained untransfected (lanes 4).
that was present on the transfected plasmids (Figure 4b , c). In addition, we performed FACS analyses for EGFP expression to confirm comparable transfection efficiencies (Figure 4a, c) . In all cases, between 85% and 90% of the cells were transfected. Bands specific for EGFP (Figure 4a ), SOD-1 ( Figure 4b ) and ␣-synuclein ( Figure  4c ), as well as the bands corresponding to the internal control proteins were quantitated by densitometry (for details, see Materials and methods). Densitometric quantitation revealed that EGFP was expressed at nine-fold higher levels, ␣-synuclein at 11.9-fold higher levels and SOD-1 at 3.2-fold higher levels than from the corresponding IRES vectors. Similar results were found in repeat experiments. These results indicate that 2A-mediated cleavage can confer at least comparable and, in some cases, significantly higher levels of second gene expression than IRES-dependent translation.
The C-terminal 2A tail does not inhibit SOD-1 enzymatic activity In our experiments, 2A-mediated cleavage of a fusion protein results in the addition of 23 (2A) amino acids to the C-terminus of the first gene product, and the incorporation of a single proline at the N-terminus of the second protein. To study whether these modifications may inhibit protein activity, we measured the SOD-1 activities in lysates of 293T cells transfected with psubCMV-SOD1-2A-EGFP or psubCMV-EGFP-2A-SOD1 using a colorimetric kinetic assay. As controls, we used psubCMV-SOD1-transfected and psubCMV-EGFP-IRES-SOD1-transfected cells that express full-length wild-type SOD-1. In addition, psubCMV-EGFP-transfected cells were used to determine endogenous SOD-1 activity. In all cases, transfection efficiencies were comparable (85- 
g total protein per lane was separated by SDS-PAGE, transferred to a PVDF membrane and analyzed by immunoblot. (a) Blot probed with a rabbit polyclonal antibody against EGFP and (simultaneously) a sheep polyclonal antibody against human SOD1 (internal standard). Cells were transfected with plasmid CMV-syn-2A-EGFP (lane 1), CMV-syn-IRES-EGFP (lane 2), positive control plasmid CMV-EGFP (lane 4), or remained untransfected (lane 3). (b) Blot probed with a sheep polyclonal antibody against human SOD1 and a rabbit polyclonal antibody against EGFP (internal control). Cells were transfected with plasmid CMV-EGFP-2A-SOD1 (lane 1), CMV-EGFP-IRES-SOD1 (lane 2), positive control plasmid CMV-SOD1 (lane 4), or remained untransfected (lane3). (c) Blot probed with a mouse monoclonal antibody against human ␣-synuclein and a rabbit polyclonal antibody against EGFP (internal control). Cells were transfected with plasmid CMV-EGFP-2A-syn (lane 1), CMV-EGFP-IRES-syn (lane 2), positive control plasmid CMV-syn (lane 4), or remained untransfected (lane 3).
90%). Table 1 shows that transfection increased SOD-1 activity 2.0-3.6-fold relative to the endogenous activity, depending on the construct. No difference in SOD-1 activity was seen between psubCMV-SOD1-transfected and psubCMV-SOD1-2A-EGFP-transfected cells, indicating that the C-terminal 2A tail of SOD1-2A does not inhibit the enzymatic activity of SOD-1. SOD-1 activities were also comparable in psubCMV-EGFP-2A-SOD1-transfected and psubCMV-EGFP-IRES-SOD1-transfected cells. Correction for the protein concentration of each Gene Therapy sample (lysate) and subtraction of endogenous SOD-1 activity revealed that neither the C-terminal 2A tail (SOD1-2A) nor the N-terminal proline (Pro-SOD1) inhibited SOD-1 activity (Table 1) . Similarly, our results described above show that both EGFP-2A and Pro-EGFP are green fluorescent. Since the function of ␣-synuclein is unknown, we were not able to carry out experiments to address the influence of the 2A tail on this protein.
Confirmation of co-expression of ␣-synuclein and EGFP in transfected cells by confocal microscopy To demonstrate that ␣-synuclein and EGFP fused inframe via the 2A sequence were co-expressed in the same cells, we identified EGFP-positive cells by direct confocal fluorescence microscopy and ␣-synuclein-expressing cells by immunocytochemistry with a monoclonal antibody against ␣-synuclein. Most, if not all cells transfected with the plasmid CMV-syn-2A-EGFP expressed both ␣-synuclein and EGFP (Figure 5a-c) . However, EGFP was expressed uniformly in the cytoplasm whereas ␣-synuclein appeared to be enriched around membranes and at the periphery of the cells (Figure 5b, c) . The expression patterns and levels of the two proteins were comparable to those observed in cells transfected with the corresponding positive control plasmids CMV-EGFP ( Figure 5d ) and CMV-syn (Figure 5e ), respectively.
Bicistronic rAAV vectors based on the FMDV 2A sequence confer efficient gene expression in the rat brain To assess whether 2A-based bicistronic expression vectors can mediate efficient gene expression in vivo (ie in the rat brain) and to compare them side by side with an IRES-dependent vector, we generated rAAVs expressing ␣-synuclein and EGFP linked via the 2A or IRES sequence under the control of the human PDGF-␤ chain promoter (Figure 1i-k) . This promoter was chosen because it has been successfully used to target the expression of proteins to neurons in transgenic models of neurodegenerative disease 43, 44 Comparable infectious titers (10 5 infectious units) of HPLC-purified rAAV particles were injected unilaterally into the substantia nigra of adult rats (three rats per vector type). Injection of either rAAV-EGFP-2A-syn or rAAV-syn-2A-EGFP resulted in readily detectable and comparable expression of both ␣-synuclein and EGFP in all animals 4 weeks after virus injection (Figure 6a-d) . In contrast, while expression of ␣-synuclein by rAAV-syn-IRES-EGFP was similar to the 2A vectors, EGFP levels were much lower than those achieved with the 2A vectors (Figure 6e, f) . There was a weak signal for ␣-synuclein in the uninjected hemisphere representing endogenous rat protein due to cross-reactivity of the polyclonal antibody to rat ␣-synuclein (Figure 6g) . The in vivo expression data are in good agreement with the immunoblot results that also showed higher protein levels when EGFP was encoded downstream of the 2A sequence as compared with being positioned downstream of the IRES element (Figure 4a) .
To confirm co-expression of ␣-synuclein and EGFP in neurons transduced with the 2A-dependent rAAVs, we analyzed higher magnifications of the brain sections by confocal microscopy. The two proteins were co-expressed in the majority of infected neurons (Figure 7a-f) . However, occasional single-positive cells were also observed, 293T cells were transfected in 10-cm plates by the calcium-phosphate precipitation method with 30 g of the indicated plasmids. EGFP served as an internal control for transfection efficiency. In all cases, transfection efficiencies were comparable (85-90%). Thirty hours after transfection, the cells were collected, washed with PBS and lysed in 1% Triton X-100, 10 mm Tris-HCl pH 8.0, 0.14 m NaCl containing complete protease inhibitor cocktail (Roche Molecular Biochemicals). Protein concentrations were determined with the BCA protein assay kit (Pierce). Lysates were cleared by centrifugation and extracted with 1.6 volumes of ethanol/chloroform (6.25/3.75). The SOD-1 activity of each sample was determined in triplicate in the aqueous phase using the superoxide dismutase assay kit (Calbiochem) perhaps owing to the apparently distinct subcellular localization of ␣-synuclein and EGFP.
Discussion
Many acquired diseases are now being considered for treatment by gene therapy, including AIDS, cancer and neurodegenerative diseases. Often, the underlying defect and pathogenic mechanisms are unknown or poorly defined in these disorders. Consequently, treatments may attempt to interfere with various (postulated) pathways simultaneously (eg oxidative stress and apoptosis in neurodegeneration) or inhibit virus propagation at different levels (eg inhibition of replication and selective killing of virus-infected cells). Thus, it may be desirable to coexpress two or more genes simultaneously in the same cells. Furthermore, co-expression of a reporter gene with a therapeutic gene is frequently desired to select genetically modified cells ex vivo or identify transduced cells in vivo. Previously, different genes have been delivered either by separate viral vectors 14, 45 or bicistronic vectors incorporating the IRES. [24] [25] [26] While the first approach is laborious and time-consuming, the second strategy can be limited by the reduced expression of the gene inserted downstream of the IRES. 28, 31 In addition, the IRES ocupies a relatively large portion of the cloning capacity of some vectors (eg rAAV).
In FMDV, the primary cleavage of the polyprotein occurs in cis and requires the 16 amino-acid long 2A sequence that mediates cleavage at its own Cterminus. 32, 34 The mechanism by which the 2A sequence promotes this cleavage is not fully understood. It has been proposed that 2A represents either (a) a recognition site for a fairly ubiquitous protease associated with eukaryotic ribosomes; (b) an unusually short novel element of protein cleavage; or (c) a sequence that results in a failure to synthesize a peptide bond, yet allows the continuation of translation. 33, 46 Regardless of the actual mechanism, the utility of the 2A sequence for the coordinate expression of two heterologous proteins has been demonstrated previously in plants 36, 37 and cultured mammalian cells. [38] [39] [40] In this work, we have further explored the potential of the FMDV 2A sequence for the co-expression of two genes in cultured cells, and quantitatively compared the levels of second gene expression mediated by 2A-and IRES-dependent vectors for three different proteins. Furthermore, we generated 2A-dependent recombinant adeno-associated viruses and studied, for the first time, the utility of the 2A system for direct in vivo gene expression by intracerebral injection of rats with rAAV vectors carrying ␣-synuclein and EGFP coding sequences fused in-frame via 2A.
The 2A sequence efficiently promoted the generation of the predicted cleavage products from four different fusion proteins in transfected cells. We also show that 
infectious units of rAAV-PDGF-EGFP-2A-syn (a, b), rAAV-PDGF-syn-2A-EGFP (c, d), or rAAV-PDGF-syn-IRES-EGFP (e, f). Expression of EGFP (a, c, e) and ␣-synuclein (b, d, f, g) was analyzed by fluorescence microscopy in coronal sections of the substantia nigra 4 weeks after rAAV injection, either directly (EGFP), or after incubation with a mouse monoclonal antibody against ␣-synuclein and a Cy3-conjugated secondary antibody against mouse immunoglobulins. Note that panel e has been overexposed for easier recognition of EGFP expression. This can be seen from the increased diffuse green background compared with panels a and c. (g) Section of the right uninjected hemisphere, showing low level expression of endogenous rat ␣-synuclein (same exposure conditions as in b, d and f). Magnification ×32.
2A-mediated cleavage functions in cells infected with a rAAV carrying the SOD1-2A-EGFP expression cassette. In agreement with a previous report, 42 2A-mediated processing was completely dependent on the conserved NPGP motif, since mutation of NPGP to AAAA fully prevented the generation of the cleavage products. In contrast, the presence of an additional 35 kDa protein, that was detected with the anti-␣-synuclein antibody in cells transfected with plasmid syn-2A-EGFP, was not affected by the NPGP to AAAA mutation. This indicates that the 35 kDa protein was not generated by 2A-dependent cleavage at a 'cryptic' position within EGFP. This conclusion is consistent with the absence of any EGFP amino acid sequences similar to those at the C-terminus of 2A (as revealed by close inspection of the EGFP primary sequence). In addition, the 35 kDa protein can not be derived from the syn-2A cleavage product by posttranslational modification, since syn-2A disappeared upon mutation. Therefore, we believe that the 35 kDa protein most likely represents a degradation product of the syn-2A-EGFP precursor. We found that genes can be efficiently expressed from 2A vectors irrespective of whether they are fused upstream or downstream to the 2A sequence (half to twothirds of the precursors cleaved, Figures 2 and 3) . Some (but not all) previous studies with in vitro translation systems 32 and transgenic plants 37 reported nearly complete cleavage of the precursor protein by 2A. However, similar to our findings, within the context of a poliovirus vector, 2A-mediated cleavage was (also) not complete. 47 It is conceivable that cleavage efficiency is influenced to some degree by the surrounding sequences and structural protein domains, 48 the amount of precursor expressed, and the cell type. A model for the nonstoichiometric, cotranslational protein scission by 2A has recently been proposed 46 that may explain some of these observations. Importantly, despite incomplete processing, the expression levels of both EGFP and ␣-synuclein were consistently and substantially higher in transfected cells when the proteins were encoded downstream of 2A instead of being translated from an IRES element. SOD-1 expression was comparable or slightly higher after the 2A element. Moreover, in the brain EGFP fluorescence after injection of the syn-2A-EGFP rAAV was significantly stronger than after injection of a comparable infectious dose of the syn-IRES-EGFP rAAV. We conclude that 2A-dependent rAAVs confer at least comparable and, in some cases, substantially higher expression levels of the downstream-positioned gene when compared with an otherwise identical IRES vector. Our experiments do not address the mechanism resulting in increased protein expression. While we believe that this is due to increased translational efficiency of the 2A system, 46 we can not rule out a differential effect of the 2A and IRES elements on transcription and mRNA stability.
Gene Therapy
Most, if not all neurons infected with the 2A-dependent rAAVs co-expressed EGFP and ␣-synuclein at high levels. Although we have not formally shown 2A-mediated cleavage in the brain (this is technically not feasible), the distinct subcellular localizations of EGFP (homogenous in cytoplasm) and ␣-synuclein (enriched around membranes) in transduced neurons strongly suggests that cleavage indeed occurs (if only the fusion protein were expressed, we would expect colocalization of the two signals for EGFP and ␣-synuclein). Moreover, we observed the same subcellular pattern of EGFP and ␣-synuclein expression by confocal microscopy in transfected cells, where we convincingly show cleavage by 2A on immunoblots.
Our findings that 2A-mediated expression of genes is at least as efficient as from the IRES, combined with the small size of the 2A sequence (72 bp as opposed to 500 bp of the IRES), makes the 2A element particularly attractive in gene therapy vectors with limited cloning capacity like rAAV or retroviral vectors. 40 The small size of the 2A element may be useful for the coordinate expression of several enzymes to reconstitute a complete biosynthetic pathway, which may result in increased therapeutic benefit in some instances. 14, 45 In tumor gene therapy, combinations of immunostimulatory, antiangiogenic and suicide genes may be expressed simultaneously from a single vector to maximize antitumor effects. [49] [50] [51] Moreover, effective vaccination against two or more tumor or viral antigens expressed at high levels from one vector may be feasible. Other applications may include the coordinate synthesis of IL-12 subunits that must be expressed at similar levels in order to achieve maximal cytokine activity. 38 Finally, the 2A system should be useful to co-express therapeutic genes with a readily detectable reporter gene or cell-surface marker, in order to identify and track transduced cells in vivo, and to determine accurately the titer of transducing units of different types and batches of rAAVs by flow cytometry. 52 A potential drawback of the 2A system may be that the 23 amino acids being added to the C-terminus of the protein encoded upstream of 2A might influence the function or activity of some proteins. However, this has not been observed for proteins and enzymes tested to date, including SOD-1 and EGFP (this study), chloramphenicol acetyltransferase, 37, 38 puromycin Nacetyl transferase, ␤-glucuronidase and alkaline phosphatase. 40, 41 Furthermore, our finding that genes can be expressed effectively when fused upstream or downstream of 2A suggests that modification-sensitive proteins could be encoded from the second cistron after 2A. This would result in the addition of only one proline to the N-terminus, which is not expected to interfere with protein function, in agreement with our findings and previous reports. 37, 38, 40, 41 The immunogenicity of the 2A peptide remains to be determined. A priori, we do not expect the 2A peptide to be more immunogenic than other foreign epitopes expressed as part of a transgene product. Our results show that the 2A sequence does not compromise rAAVmediated transgene expression in vivo for at least 1 month, since EGFP and ␣-synuclein levels in the brain were comparable to those achieved with rAAVs lacking 2A. 52 However, whether or not the 2A peptide may increase immunity against other transgene products, or after gene delivery by a different route or by more immunogenic viral vectors, remains to be addressed.
Infection of cells by picornaviruses results in a rapid shut-off of host protein synthesis due to virus-induced cleavage of specific eukaryotic translation initiation factors (eIF-4␥). 32 In enteroviruses and rhinoviruses this cleavage is dependent on the large 2A proteases. 32 In addition, coxsackie B virus protease 2A has been shown to result in the cleavage of dystrophin. 53 The situation in aphtoviruses (ie FMDV) is different; eIF-4␥ cleavage is mediated by the virally encoded L proteinase and not by the 2A sequence. [54] [55] [56] [57] In the case of FMDV, the 2A sequence is much shorter (only 16 amino acids) and it lacks any homology to other known viral and cellular proteases, indicating that FMDV 2A is in fact not a protease, but most likely mediates protein scission by a unique mechanism. 32 This is supported by experiments showing that the Gly-Pro amide bond (within NPGP) is actually not synthesized, and that the observed 'cleavage' may be the result of hydrolysis mediated by a ribosomally bound 2A polypeptidyl-tRNA. 46 Finally, FMDV 2A-mediated cleavage of the viral polyprotein and of artificial target proteins is absolutely dependent on the conserved NPGP motif. 42 This motif is different from the known recognition motifs of the other picornaviral 2A proteases. 53, 57 Within current databases, the NPGP motif is only found in proteins from cardioviruses, aphtoviruses (FMDV) and group C porcine retroviruses. Taken together, we consider it extremely unlikely that the FMDV 2A peptide will result in the 'cleavage' of endogenous host proteins.
In summary, our results extend previous findings of 2A-mediated gene expression, specifically show that 2A-dependent vectors confer at least comparable protein levels when directly compared with IRES-containing vectors and, most importantly, provide the first demonstration of in vivo gene transfer and expression with a 2A-dependent gene therapy vector. We conclude that 2A-containing bicistronic rAAVs may be an attractive alternative to IRES-dependent vectors for ex vivo and in vivo gene expression, in particular when the cloning capacity is limited and high levels of the second gene product are required. Future studies addressing the function and safety of 2A-dependent vectors in additional tissues and their suitability to co-express proteins targeted to different cellular compartments will be important to further advance this system. (Figure 1f ) was constructed by insertion of the EGFP fragment at the 3Ј end of the EMCV IRES contained within pBLSK-IRES 58 to generate plasmid pBLSK-IRES-EGFP. The IRES-EGFP fragment was recovered from pBLSK-IRES-EGFP and subcloned into psubCMV-WPRE to generate psubCMV-IRES-EGFP-WPRE. Finally, the PCR-amplified ␣-synuclein ORF was inserted into psubCMV-IRES-EGFP-WPRE to generate psubCMV-syn-IRES-EGFP (Figure 1f ). To generate plasmids expressing SOD-1 and ␣-synuclein (syn) from the IRES, the two open reading frames were amplified by PCR, generating fragments flanked by NcoI sites. The NcoI-digested PCR products were inserted into the NcoI site following the IRES element in pBLSK-IRES 58 to generate pBLSK-IRES-SOD1 and pBLSK-IRES-syn. Subsequently, the SmaI/HpaI EGFP fragment from pEGFP-N1 (Clontech) was inserted into the Klenow polymerase-filled XbaI site of pBLSK-IRES-SOD1 and pBLSK-IRES-syn to generate plasmids pBLSK-EGFP-IRES-SOD1 and pBLSK-EGFP-IRES-syn. Finally, the EGFP-IRES-SOD1 and EGFP-IRES-syn fragments were recovered from the Bluescript vectors and inserted into the PmlI site of psubCMV-WPRE 52 to generate the plasmids psubCMV-EGFP-IRES-SOD1 (Figure 1g ) and psubCMV-EGFP-IRES-syn (Figure 1h ). psubPDGFsyn-IRES-EGFP (Figure 1k ) was obtained by isolating the syn-IRES-EGFP-WPRE fragment from psubCMV-syn-IRES-EGFP, and subcloning it into psubPDGF. 52 All constructs used in expression analyses contained the woodchuck hepatitis post-transcriptional regulatory element 59 after the second coding sequence and before the SV40 polyadenylation signal. All plasmids were sequenced to confirm sequence identity.
Materials and methods

Plasmid constructions
Transfections
For Western blot experiments, 2.5 × 10 6 293T cells in 60-mm plates were transiently transfected with 8 g of the various plasmids by the calcium-phosphate coprecipitation method. Comparable transfection efficiencies were confirmed by determining the percentage of EGFPpositive cells by flow cytometry. In all cases, between 85 and 90% of the cells expressed EGFP. For confocal microscopy, triplicate wells of 293T cells grown on glass cover slips in 12-well plates were transfected with 2 g plasmid DNA per well.
Western blot analysis
Twenty or 40 g of total cellular proteins per lane were separated on 12.5% SDS polyacrylamide gels, and transferred to PVDF membranes (BioRad, Hercules, CA, USA) by semi-dry electroblotting. Primary antibodies were 1:1000 diluted mouse monoclonal antibody against ␣-synuclein (Zymed, South San Francisco, CA, USA), 1:300 diluted rabbit polyclonal peptide antibody against EGFP (Clontech) and 1:1000 diluted sheep polyclonal anti-SOD-1 antibody (Juro AG, Lucerne, Switzerland). Secondary reagents were 1:4000 diluted anti-mouse immunoglobulin-HRP (Roche Molecular Biochemicals, Rotkreuz, Switzerland) and 1:3000 diluted protein G-HRP (BioRad). The blots were developed using the ECL enhanced chemiluminescence system (Amersham, Dü bendorf, Gene Therapy Switzerland). Prestained SDS-PAGE low range standard (BioRad, 161-0305) was used as a protein size marker.
Densitometry
For quantitative comparison of second gene product expression by 2A-mediated cleavage and IRESdependent translation, the specific bands on the autoradiographs were scanned in the Personal Densitometer (Molecular Dynamics, Sunnyvale, CA, USA). We scanned short exposures of the blots to ensure that all signals were within the linear range of measurable optical densities of the instrument. Endogenous gene expression levels of untransfected cells were subtracted where necessary (SOD-1 quantitation) , and the signals were adjusted relative to those of internal standards. Internal standards were EGFP (Figure 4b, c) and endogenous SOD-1 ( Figure  4a ). For 2A-dependent constructs, the sum of the two EGFP-immunoreactive bands was taken for standard calculation. In addition, transfection efficiencies were controlled by flow cytometry for EGFP-expressing cells and found to be between 85 and 90% for all samples.
SOD-1 activity assay SOD-1 activity was determined with the superoxide dismutase assay kit from Juro AG. Briefly, 5 × 10 6 293T cells were transfected in 10-cm plates by the calcium-phosphate precipitation method with 30 g of psubCMV-SOD1-2A-EGFP, psubCMV-EGFP-2A-SOD1, psubCMV-EGFP-IRES-SOD1, psubCMV-SOD1 plus psubCMV-EGFP or psubCMV-EGFP. Since EGFP was expressed from all constructs, we used it as an internal control for transfection efficiency. In all cases, transfection efficiencies were comparable (85-90%). Thirty hours after transfection, the cells were collected, washed with PBS and lysed in 1% Triton X-100, 10 mm Tris-HCl pH 8.0, 0.14 m NaCl containing complete protease inhibitor cocktail (Roche Molecular Biochemicals). Lysates were cleared by centrifugation and extracted with 1.6 volumes of ethanol/chloroform (6.25/3.75). The SOD-1 activity of each sample was determined in triplicate in the aqueous phase according to the manufacturer's instructions, adjusted for the protein concentration of each sample and corrected for endogenous SOD-1 activity of psubCMV-EGFP-transfected cells.
Analysis of EGFP and ␣-synuclein expression in transfected 293T cells by confocal microscopy 293T cells were fixed for 15 min with 4% paraformaldehyde in PBS. EGFP was detected by direct fluorescence microscopy in the FITC channel. ␣-Synuclein was detected by immunocytochemistry with 1:200 diluted mouse monoclonal antibody against ␣-synuclein (Zymed) and secondary Cy3-conjugated donkey antimouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) at a dilution of 1:200. ␣-Synuclein expressing neurons were visualized using a Cy3-selective filter set.
Preparation of rAAV and infection of cells
Recombinant AAVs were generated as described 9 and purified by iodixanol gradient centrifugation and heparin affinity chromatography. 60 Infectious titers of the purified rAAVs were determined by the replication center assay. 61 Titers were 5.2 × 10 7 IU/ml for rAAV-PDGF-syn-2A-EGFP, 4.8 × 10 7 IU/ml for rAAV-PDGF-EGFP-2A-syn, and 4.6 × 10 7 IU/ml for rAAV-PDGF-syn-IRES-EGFP. The titer of the rAAV-CMV-SOD1-2A-EGFP vector was determined by slot blot hybridization 61 and found to be 10 11 particles/ml. Cells were infected with 3000 particles of the vector per cell (for the experiment shown in Figure 2c ).
Stereotactic injections and analysis of gene expression in brain
Nine-week-old male Wistar rats were stereotactically injected with 2.2 l rAAV (10 5 IU) above the left substantia nigra (AP −5.0 mm; ML +3.0 mm; DV −7.2 mm relative to bregma) at a speed of 0.5 l/min using a sp200i syringe pump (World Precision Instruments, Boston, MA, USA) and a 10 l Hamilton syringe fitted with a 26-gauge steel cannula. Four weeks later, 40 m coronal cryosections of the substantia nigra were cut on a microtome (Microm, Walldorf, Germany). EGFP expression was visualized by direct fluorescence microscopy. ␣-Synuclein was detected by immunohistochemistry with a rabbit polyclonal antibody against human ␣-synuclein (1:500 dilution) (Chemicon, Temecula, CA, USA), followed by 1:800 diluted donkey anti-rabbit IgG conjugated to Cy3 (Jackson ImmunoResearch Laboratories).
Imaging
Images were captured by a Zeiss microscope (Carl Zeiss, Feldbach, Switzerland) connected to a Hamamatsu CCD camera for low magnification brain sections, or by confocal microscopy (Leica, Glattbrugg, Switzerland) for high magnification brain sections and 293T cells, using FITC and Cy3 filter sets, respectively. Images were transferred to a Macintosh computer, and processed using the Adobe Photoshop 5.0 software.
